US equities
|
SPCX
$174.88
▲+2.22%
NVDA
$242.34
▲+1.44%
MU
$1,064.84
▲+0.08%
MRVL
$291.20
▲+7.36%
AMD
$648.80
▲+2.70%
SNDK
$1,668.96
▼-2.07%
AVGO
$376.60
▲+3.89%
TSLA
$380.62
▲+0.50%
SPCX
$174.88
▲+2.22%
NVDA
$242.34
▲+1.44%
MU
$1,064.84
▲+0.08%
MRVL
$291.20
▲+7.36%
AMD
$648.80
▲+2.70%
SNDK
$1,668.96
▼-2.07%
AVGO
$376.60
▲+3.89%
TSLA
$380.62
▲+0.50%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Oncotelic Therapeutcs Inc
(OP:
OTLC
)
0.0217
UNCHANGED
Delayed Quote
Updated: 9:38 AM EDT, Oct 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Oncotelic Therapeutcs Inc
< Previous
1
2
3
4
5
6
7
Next >
Oncotelic Therapeutics Inc. (OTLC) Holds $388M JV Valuation as Pipeline Momentum Builds
June 01, 2026
Via
Investor Brand Network
TechMediaBreaks – Nightfood Holdings Inc. (OTCQB: NGTF) Subsidiary TechForce Deploys Autonomous Lab Robot in Pharmaceutical Automation Milestone
June 01, 2026
Via
Investor Brand Network
TechForce Robotics Enters Pharmaceutical Automation Market Through Initial Deployment at Oncotelic Therapeutics
June 01, 2026
From
Nightfood Holdings Inc.
Via
GlobeNewswire
BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) and Sapu Nano to Present Deciparticle(TM) Nanomedicine Platform at BIO International Convention 2026
May 28, 2026
Via
Investor Brand Network
Topics
Artificial Intelligence
Intellectual Property
How Advanced Drug Delivery Could Improve Existing Cancer Treatments
June 01, 2026
From
BioMedWire
Via
GlobeNewswire
Sapu Nano Unveils Progress in Deciparticle™ Nanomedicine Platform and AI-Driven Oncology Development at BIO 2026
May 28, 2026
From
Oncotelic Therapeutics, Inc.
Via
GlobeNewswire
Oncotelic Therapeutics Inc. (OTLC) Advances CNS Drug Delivery Strategy as BBB Breakthroughs Drive New Biotech Market Opportunity
May 26, 2026
Via
Investor Brand Network
Oncotelic Therapeutics Inc. (OTLC) Proving Small Biotech Can Out-Innovate Big Pharma with 28 Million Reasons Why
May 21, 2026
Via
Investor Brand Network
Topics
Artificial Intelligence
BioMedNewsBreaks — Oncotelic Therapeutics Inc. (OTLC) Expands Beyond Biotech with AI-Enhanced Robotics Strategy
May 19, 2026
Via
Investor Brand Network
Topics
Artificial Intelligence
Intellectual Property
NetworkNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in NetworkNewsAudio Editorial on CNS Drug Delivery Innovation
May 15, 2026
Via
Investor Brand Network
Topics
Intellectual Property
InvestorNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Reports First-Quarter Results, Highlights Progress Across Biotech Platform
May 15, 2026
Via
Investor Brand Network
Topics
Intellectual Property
NetworkNews Audio Announces Audio Press Release (APR) Discussing Developing Technologies Designed to Bypass BBB Limitations
May 15, 2026
From
NetworkNewsWire
Via
GlobeNewswire
BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on CNS Drug Delivery Innovation
May 14, 2026
Via
Investor Brand Network
Topics
Intellectual Property
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Responds to BBB Challenge with Next-Gen Drug-Delivery Platform
May 14, 2026
From
Oncotelic Therapeutics, Inc.
Via
GlobeNewswire
BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Announces First Patient Dosed in Phase 1b Trial of Sapu003
May 13, 2026
Via
Investor Brand Network
Topics
Intellectual Property
CNS Drug Delivery Technologies Are Reshaping Alzheimer’s and Biodefense Research
May 13, 2026
Via
Investor Brand Network
Sapu Nano Announces First Patient Dosed in Phase 1b Trial of Sapu003, an Intravenous Deciparticle™ Formulation of Everolimus
May 13, 2026
First-in-human study evaluates weekly IV Sapu003 in advanced mTOR-sensitive solid tumors, including HR+/HER2- breast cancer, RCC, NETs, TSC-associated tumors, and HCC
From
Oncotelic Therapeutics, Inc.
Via
GlobeNewswire
InvestorNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on Next-Generation CNS Drug Delivery
May 13, 2026
Via
Investor Brand Network
Topics
Intellectual Property
CNS Drug Delivery Technologies Are Reshaping Alzheimer’s and Biodefense Research
May 13, 2026
From
BioMedWire
Via
GlobeNewswire
BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on CNS Drug Delivery Innovation
May 12, 2026
Via
Investor Brand Network
Topics
Intellectual Property
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Proprietary N2B System May Offer Key to Unlocking Next-Gen Therapies
May 12, 2026
From
Oncotelic Therapeutics, Inc.
Via
GlobeNewswire
The Partnership Playbook: Oncotelic Therapeutics Inc. (OTLC) Advancing Its Pipeline Without Dilution
May 11, 2026
Via
Investor Brand Network
Topics
Initial Public Offering
Intellectual Property
CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities
May 11, 2026
Via
Investor Brand Network
InvestorNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Targets CNS Drug Delivery Opportunity as Brain Therapeutics Innovation Accelerates
May 11, 2026
Via
Investor Brand Network
Topics
Intellectual Property
Pipeline Maturity is Redefining Valuations in Biotech
May 07, 2026
Via
Investor Brand Network
BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Completes $12.5M N2B Asset Transfer to Lunai Bioworks
May 06, 2026
Via
Investor Brand Network
Topics
Intellectual Property
CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities
May 11, 2026
From
BioMedWire
Via
GlobeNewswire
Oncotelic Therapeutics Announces Closing of a Strategic Monetization of Its CNS/Nasal Assets with Lunai Bioworks, Advancing Joint Development in Biodefense and Alzheimer’s Disease
May 06, 2026
From
Oncotelic Therapeutics, Inc.
Via
GlobeNewswire
InvestorNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Advances AI and Robotics Platform Toward Initial Commercial Deployment
April 30, 2026
Via
Investor Brand Network
Topics
Artificial Intelligence
Intellectual Property
Oncotelic Therapeutics Advances Toward Commercial Launch of AI-Enabled Robotics Platform Following Integration of 28 Million Scientific Abstracts
April 30, 2026
From
Oncotelic Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
Next >
